News | Artificial Intelligence | May 31, 2019

AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy

Lunit presenting findings from study at ASCO 2019

AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy

May 31, 2019 — Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019, held May 31 – June 4 in Chicago. The accepted abstract highlights the feasibility of AI-based biomarkers in metastatic non-small cell lung cancer, based on the H&E analysis that predicts response to immune checkpoint inhibitors (ICI).

The study evaluated the predictive value of AI versus PD-L1, the main biomarker for ICI, in terms of both its comparative predictive value as well as additive predictive value. According to the research, within PD-L1(+) patient group, the treatment response and progression-free survival (PFS) significantly differed depending on the AI score. The same results were obtained within the PD-L1(-) group.

After reclassifying PD-L1(-) patient group based on the AI score, 52 percent of patients with high AI score had, in fact, shown response to ICI. These patients had three times longer PFS compared to the patients who had a low AI score. Similar outcomes were found among the PD-L1(+) patient group. Classified with AI profiling, 63 percent of low AI score patients were non-responsive to ICI. These patients had six times shorter PFS compared to high AI score patients.

Additionally, in an AI analysis independent of PD-L1, the team was able to identify more patients that showed response to ICI. Among PD-L1(+) patient group, 49 percent of the patients were responsive to ICI, whereas 65 percent of patients within high AI score patient group showed response.

Read the full ASCO abstract here.

For more information: www.lunit.io

Related Content

Breast Tomosynthesis Increases Cancer Detection Over Digital Mammography
News | Mammography | October 23, 2019
Screening digital breast tomosynthesis (DBT) results in “significantly increased CDR [cancer detection rates]” compared...
NVIDIA and King's College London Debut First Privacy-preserving Federated Learning System

Image courtesy of NVIDIA

News | Artificial Intelligence | October 23, 2019
To help advance medical research while preserving data privacy and improving patient outcomes for brain tumor...
Major Radiology Organizations Publish Ethics of AI in Radiology Statement
News | Artificial Intelligence | October 22, 2019
Experts in the use of artificial intelligence (AI) in radiology, from many of the world’s leading radiology, medical...
Greater Left Ventricular Mass Increases Risk of Heart Failure
News | Cardiac Imaging | October 21, 2019
Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of coronary artery...
Densitas Breast Density Assessment Software Joins Nuance AI Marketplace
News | Breast Density | October 21, 2019
Densitas Inc. announced that its U.S. Food and Drug Administration (FDA)-cleared densitas densityai breast density...
FDA Clears AiCE Image Reconstruction on Canon's Aquilion Precision CT

Image courtesy of Canon Medical Systems

Technology | Computed Tomography (CT) | October 21, 2019
Canon Medical Systems USA Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance on its Advanced...
The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Selecting an AI Marketplace for Radiology: Key Considerations for Healthcare Providers
Feature | Artificial Intelligence | October 18, 2019 | Sanjay Parekh, Ph.D.
October 18, 2019 — As the nascent market for...
MaxQ AI's Intracranial Hemorrhage Software to be Integrated on Philips CT Systems
News | Artificial Intelligence | October 18, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that its Accipio intracranial hemorrhage (ICH...